Figure 4. Nucleocapsid-specific humoral responses do not prevent SARS-CoV-2 infection.

(A) Experimental approach for performing FRNT assays on Vero cells using live SARS-CoV-2 (USA-WA1/2020). See Methods for technical information. (B) Representative wells showing the frequencies of SARS-CoV-2⁺ cells (1:450 sera dilution). (C) Summary of FRNT₅₀ titers in sera. Ad5-E, Ad5-empty (control). Data are from week 3 after vaccination and are from 1 experiment. n = 5 per group. The experiment was performed twice with similar results. Significance was determined using the Kruskal-Wallis test (for multiple comparisons).